Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Challenge of Maintaining Therapeutic Benefits over the Long Term: Example of Adding 4 Reactivation Sessions to a Cognitive-Behavioural Fatigue Management Program for People with Relapsing-Remitting Multiple Sclerosis.
Aging, Dementia, and Behavioral Neurology
P14 - Poster Session 14 (8:00 AM-9:00 AM)
10-005

To assess the effect of 4 booster sessions to the FACETS program to obtain a long-term effect (1 year). 

Fatigue is one of the most frequent reported symptoms in Multiple Sclerosis (MS) and is usually considered to be one of the three worst symptoms with gait and genito-sphincteral disorders. Fatigue, an invisible symptom, affects social and professional relationships and decreases quality of life.

Pharmacological and non-pharmacological therapies are available, but evidences for effectiveness are limited. To date, three RCTs using cognitive-behavioral approaches (CBT) in the context of MS have been conducted (Van Kessel, 2007; Grossman, 2010, Thomas et al., 2013).  Nevertheless, the positive effect of treatment wears off over time. Thus, booster session might enhance the benefits on the long term by reinforcing the internalizations processes. FACETS, developed by Thomas and al in 2013, is promising. It is a six once-weekly sessions program focused on CBT and energy conservation, delivered in small groups, easy to implement in medical services or associations.

Multicentric RCT comparing FACETS versus local practice in pwMS.  Six once-weekly sessions followed by 4 booster sessions at regular intervals. The main criteria is the impact of CBT on fatigue evaluated by the Modified Fatigue Impact Scale (MFIS) at 1 year.

N=105 patients recruited (F=89 VS    M=16): Mean age (years) = 46 (9,99), Mean EDSS = 2.61 (1,45). The average MFIS score is 54,59 (14,16), a score above 45 means that fatigue. Results at 6 weeks and 6 months will be presented during congress.

The programme is designed to facilitate use within health services. Thus, if the results from this trial are positive on the long term, there is potential for directly adding to the treatment options available to people with MS who have troublesome fatigue and improving the services available to them.

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Olivier Heinzlef, MD (Hospital De Poissy) Dr. Heinzlef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Heinzlef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Heinzlef has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Edimark.